Trelleborg Sealing Solutions, Tustin ( formerly Specialty Silicone Fabricators)  continues to generate traction with its activity involving implantable combination products. The growing list of active pharmaceutical ingredients (API’s) used at TSS now includes the following: Dexamethasone, Cyclosporine, Chlorhexidine, Diclofenac, Doxycydine, Fluocinolone actetinide, LNG, Ivermectin, Levonorgestrel, Gentamycin, Progesterone, Rifampin, Minocycline and Lidocaine. Having completed all the necessary certifications and qualifications necessary for handling implantable products, and coupled with its sales partner in Europe,  MER (Medical Engineering Resources) TSS is ready to assist in the development of your combination products requirements.

Why combination products? The elimination of hospital born infections has many device manufacturing companies seeking greater reduction in the formation of bacteria on the surfaces of catheters. Antibiotics have shown to have greater efficacy than metallic additives in catheter bodies. Additionally, many companies in the pharmaceutical sector are looking at ways to fill “dry holes” by offering localized delivery of drugs to specific targeted sites directly through drug/device combination products.

Silicone is an ideal platform for these devices for several factors. It has high free volume which provides exceptional permeability for elution of various drugs. Silicone is, for example, 1000 times more permeable to progesterone than is polyethylene. It can be fabricated into intricate configurations for successful implantation into any part of the anatomy.

Download: TSS’s perspective and capabilities on Drug Device Combination Products

Drug-Device-Combination-Products-SSF-Perspective-and-capabilities-1